Skip to content
Screener

ANI Pharmaceuticals ANIP Total Revenue

Total Revenue at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$796.2M+9.9%
Viatris logo
ViatrisVTRS
$3.76B+4.9%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$25.56M-8.0%
ALN
Alnylam PharmaceuticalsALNY
$1.29B+66.9%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$24.27M+40.4%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$83.22M+18.9%

Segments

By product

See full
Cortrophin Gel$117.13M+43.5%
Generic pharmaceutical products$99.05M+9.7%
ILUVIEN and YUTIQ$18.72M-16.1%
Brand royalties and other revenues$17.73M—
Brands$11.81M-10.5%
Other generic revenues$1.61M—

By segment

See full
Rare Disease and Brands$165.39M+41.2%
Generics and Other$100.66M+6.8%

Other financials

Income statement

See full
Gross profit$165.9M+21.3%
Operating income$40.5M+191%
Net income$24.7M+189%
EPS (diluted)$1.05+192%

Balance sheet

See full
Cash & equivalents$360.2M+65.4%
Total debt$301.5M-4.2%
Total equity$597.2M+36.7%
Total assets$1.5B+11.3%

Cash flow

See full
Operating cash flow$56.7M-25.3%
CapEx$3.1M-23.9%
Free cash flow$53.6M-25.3%

Valuation

See full
Market cap$1.88B+25.6%
Enterprise value$1.82B+14.3%
P/E17.3×—
P/S1.9×-0.1×

Profitability

See full
Gross margin60.4%-0.7pp
Operating margin15.4%—
Net margin11.1%+10.0pp
FCF margin17.7%+0.9pp

Returns & leverage

See full
Return on equity21%+19.1pp
Debt / equity0.5×-0.2×
Current ratio2.9×+0.4×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 7:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001023024-26-000069
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net Revenues$266,044$211,371$503,506$408,493
Operating Expenses
Cost of sales (excluding depreciation and amortization)100,15874,615193,740147,652
Research and development14,74716,53525,34727,099
Selling, general, and administrative91,66181,771165,316158,299
Depreciation and amortization19,64023,28140,55946,172
Contingent consideration fair value adjustment(622)1,277(804)(10,815)
Total Operating Expenses, net225,584197,479424,158368,407

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is ANI Pharmaceuticals's total revenue?
ANI Pharmaceuticals (ANIP) reported total revenue of $266.04M in Q2 2026.
How has ANI Pharmaceuticals's total revenue changed year-over-year?
ANI Pharmaceuticals's total revenue increased by 25.9% year-over-year, from $211.37M to $266.04M.
What is the long-term trend for ANI Pharmaceuticals's total revenue?
Over 4 years (2021 to 2025), ANI Pharmaceuticals's total revenue has grown at a 42.2% compound annual growth rate (CAGR), from $216.14M to $883.37M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about ANI Pharmaceuticals's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude